World Journal of Gastrointestinal Oncology最新文献

{"title":"Application of single-cell sequencing in the study of immune cell infiltration in inflammatory bowel disease and colorectal cancer.","authors":"Zheng Zhang, Hui-Min Wang, Zhen-Xi Xu, Wen-Yu Luan, Si-Xiang Lin, Yan-Dong Miao","doi":"10.4251/wjgo.v17.i6.107382","DOIUrl":"10.4251/wjgo.v17.i6.107382","url":null,"abstract":"<p><p>The rapid advancement of single-cell sequencing (SCS) technology has provided new insights into the relationship between inflammatory bowel disease (IBD) and colorectal cancer (CRC). This technique allows for detailed cellular analysis, enabling researchers to uncover the infiltration patterns of immune cells within the gut microenvironment and their roles in disease progression. This review summarizes significant research findings on the interplay between IBD and CRC, the characteristics of immune cell infiltration, and potential therapeutic targets identified through SCS. The aim is to offer references for future clinical studies and treatment strategies in this field.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"107382"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of inflammatory and nutritional markers in colorectal cancer patients with peritoneal metastasis.","authors":"Zhao Cai, Wei-De Dai, Xiong-Wei Cai","doi":"10.4251/wjgo.v17.i6.100010","DOIUrl":"10.4251/wjgo.v17.i6.100010","url":null,"abstract":"<p><p>In this article, we critically appraise the study by Wu <i>et al</i>, which investigated the prognostic value of preoperative inflammatory and nutritional markers in colorectal cancer patients with peritoneal metastasis. This retrospective cohort study included 133 patients. The findings indicate that patients with high neutrophil-to-lymphocyte ratios (NLRs) or lower hemoglobin (Hb) levels have significantly shorter overall survival (OS) than those with lower NLRs or normal Hb levels, respectively. Furthermore, age, carbohydrate antigen 199 levels, the NLR, Hb, and the peritoneal cancer index were identified as independent prognostic factors for OS. A nomogram was subsequently developed, demonstrating its ability to accurately predict the OS of colorectal cancer patients with peritoneal metastasis. This study introduces a potentially valuable prognostic tool for these patients. However, further validation in multicenter cohorts is needed to confirm its clinical applicability, to assess its limitations, and to elucidate the underlying mechanism of these identified biomarkers.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"100010"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role and mechanism of sarcosine dehydrogenase in the progression of gallbladder cancer through chemokine pathways.","authors":"Zhen Gao, Xin Zhang, Hua He","doi":"10.4251/wjgo.v17.i6.105016","DOIUrl":"10.4251/wjgo.v17.i6.105016","url":null,"abstract":"<p><strong>Background: </strong>Sarcosine dehydrogenase (<i>SARDH</i>) and <i>C-X-C</i> motif chemokine ligand 1 (<i>CXCL1</i>) have been identified as potential tumor regulators, with growing evidence linking them to cancer progression. However, their specific roles, regulatory mechanisms, and influence on key signaling pathways remain unclear.</p><p><strong>Aim: </strong>To investigate the regulatory mechanisms of <i>SARDH</i> and <i>CXCL1</i> in cancer cells and their impact on key signaling pathways.</p><p><strong>Methods: </strong>Real-time quantitative polymerase chain reaction and western blot analyses were used to assess the expression levels of <i>SARDH</i> and <i>CXCL1</i> and their effects on protein kinase B (Akt) and extracellular signal-regulated kinase (ERK) signaling pathways. Gene overexpression was induced using an expression vector, while gene silencing was achieved using short hairpin RNA and small interfering RNA. CCK-8, migration, and invasion assays were used to evaluate the impact of gene suppression and overexpression on cancer cell proliferation, migration, and invasion.</p><p><strong>Results: </strong><i>SARDH</i> silencing significantly enhanced cancer cell proliferation, whereas its overexpression suppressed proliferation in the early stages of the experiment. <i>CXCL1</i> silencing reduced cancer cell migration and invasion. <i>SARDH</i> overexpression inhibited cell migration, invasion, and adhesion while increasing apoptosis. Conversely, <i>SARDH</i> silencing reversed these effects. Furthermore, simultaneous silencing of <i>SARDH</i> and <i>CXCL1</i> strongly activated the Akt and ERK signaling pathways, indicating the potential role of these pathways in regulating cellular functions influenced by these genes.</p><p><strong>Conclusion: </strong>This study revealed that <i>SARDH</i> and <i>CXCL1</i> regulate cancer cell growth, migration, and invasion through Akt and ERK signaling pathways, highlighting their potential as therapeutic targets for cancer treatment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105016"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>RPF2</i> regulates the protein kinase B/mammalian target of rapamycin pathway in the pathogenesis of <i>Helicobacter pylori</i>.","authors":"Yan-Qiao Hua, Kai-Xin Guo, Peng Ni, Di Wang, Tong-Yan An, Yang-Ye Gao, Rong-Guang Zhang","doi":"10.4251/wjgo.v17.i6.105664","DOIUrl":"10.4251/wjgo.v17.i6.105664","url":null,"abstract":"<p><strong>Background: </strong><i>RPF2</i> is a crucial factor in ribosome synthesis, which has been linked to the development of several cancers. However, the mechanism of <i>RPF2</i> in gastric carcinogenesis is unclear.</p><p><strong>Aim: </strong>To explore the role and mechanism of <i>RPF2</i> in the pathogenesis of <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection.</p><p><strong>Methods: </strong>GES-1 was co-cultured with <i>H. pylori in vitro</i> to detect changes in the expression of <i>RPF2</i>. Overexpression and silencing of <i>RPF2</i> were performed. Quantitative real-time polymerase chain reaction (q-PCR) and Western blot (WB) were used to determine mRNA and protein expression of <i>RPF2</i>, protein kinase B (AKT)/mammalian target of rapamycin (mTOR), and epithelial-mesenchymal transition-related factors <i>MMP2</i> and <i>MMP9</i>; cell counting kit 8 and wound healing assays were utilized to evaluate cell viability and migratory capacity; q-PCR, WB, and immunohistochemistry were employed to establish <i>RPF2</i> expression in cancer tissues.</p><p><strong>Results: </strong><i>H. pylori</i> facilitated <i>RPF2</i> expression and triggered AKT/mTOR signaling pathway. Functional experiments showed that <i>RPF2</i> overexpression could promote a series of malignant transformations such as cell proliferation, cell migration and invasion, and further enhance AKT/mTOR signaling pathway activation. <i>RPF2</i> knockdown had the opposite effect. In addition, <i>RPF2</i> expression was higher in gastric cancer tissues than in adjacent tissues.</p><p><strong>Conclusion: </strong><i>RPF2</i> plays a significant role in the pathogenic mechanism of <i>H. pylori</i> infection and may be useful in the detection and management of gastric cancer caused by <i>H. pylori</i> infection.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105664"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive bone metastases from an occult gastric primary: A case report.","authors":"Chao-Bo Jin, Yong-Sheng Li, Juan Zhang, Jian Wu, Wei-Jing Tao","doi":"10.4251/wjgo.v17.i6.106848","DOIUrl":"10.4251/wjgo.v17.i6.106848","url":null,"abstract":"<p><strong>Background: </strong>This report describes a rare case of a small gastric cancer lesion with widespread bone metastases and markedly elevated alkaline phosphatase levels that was initially misdiagnosed as rheumatoid arthritis, as the patient's sole clinical manifestation was chronic bone pain persisting for 1 year.</p><p><strong>Case summary: </strong>An 83-year-old man was admitted due to worsening generalized joint pain over 1 year. Serum alkaline phosphatase levels were markedly elevated, and technetium-99m methylene diphosphonate single-photon emission computed tomography (CT) and fluorine-18 sodium fluoride positron emission tomography (PET)/CT images showed symmetrical diffuse uptake of the radiotracers throughout the skeleton. Initially, Paget's disease was suspected, but abnormal hematologic tumor markers and bone biopsy confirmed metastatic adenocarcinoma. Fluorine-18-fluorodeoxyglucose PET/CT did not reveal a primary tumor. The patient had a history of colon polypectomy and tubulovillous adenoma with atypical hyperplasia on pathological examination 10 years prior. Further investigation using gallium-68-labeled fibroblast-activation protein inhibitor PET/CT images showed increased punctate uptake in the gastric antrum. Gastroscopy demonstrated a 1.0 cm ulcerated mass in the prepyloric region, and histopathological evaluation of the biopsy specimen revealed poorly differentiated adenocarcinoma. The incidence of bone metastases from gastric cancer is very low, especially with such extensive involvement.</p><p><strong>Conclusion: </strong>Occult gastric carcinomas with bone metastases necessitate proactive high-risk surveillance and multidisciplinary integration to improve diagnostic accuracy and clinical outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106848"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift.","authors":"Giulia Massaro, Alexandra Paulet, Daniele Lavacchi, Marco Brugia, Daniele Rossini, Elisa Giommoni, Martina Catalano, Serena Pillozzi, Lorenzo Antonuzzo, Giandomenico Roviello","doi":"10.4251/wjgo.v17.i6.106707","DOIUrl":"10.4251/wjgo.v17.i6.106707","url":null,"abstract":"<p><p>Esophageal cancer is an aggressive malignancy often diagnosed at advanced stages, with esophageal squamous cell carcinoma being the predominant subtype worldwide. Standard first-line chemotherapy provides limited survival benefits, with a median overall survival of less than 1 year. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have transformed the treatment landscape, improving overall survival and progression-free survival. However, response rates remain variable, with programmed death ligand 1 (PD-L1) expression being the primary predictive biomarker. The variability in PD-L1 testing methods and immune microenvironment alterations after prior treatments complicate patient selection for ICIs. Several phase 3 trials, including KEYNOTE-590 and CheckMate 648, have demonstrated the efficacy of ICIs combined with chemotherapy, particularly in patients positive for PD-L1. Despite these advances, long-term survival remains low, emphasizing the need for better biomarkers and novel therapeutic strategies. This review explored current first-line treatment options for esophageal squamous cell carcinoma, challenges in biomarker-based patient selection, and emerging therapeutic approaches.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106707"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma.","authors":"Zhi-Hao Yang, Si-Nan Liu, Fu-Ying Chu, Cheng Yang, Xiang Chen","doi":"10.4251/wjgo.v17.i6.105170","DOIUrl":"10.4251/wjgo.v17.i6.105170","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide and currently lacks effective treatment options. This is particularly true for advanced HCC, for which conventional therapies often lead to a poor prognosis.</p><p><strong>Aim: </strong>To assess the safety and efficacy of transarterial chemoembolization (TACE) with donafenib and immune checkpoint inhibitors (ICIs) for unresectable HCC.</p><p><strong>Methods: </strong>We retrospectively assessed the data of patients with HCC who underwent TACE combined with donafenib and an ICI (tislelizumab or cedilimumab). Patients received oral donafenib daily for 2 weeks before TACE, followed by tislelizumab or cedilimumab 200 mg intravenously on day 1 of a 21-day therapeutic cycle. The primary endpoints were objective response rate, disease control rate, and duration of response according to the modified RECIST criteria. The secondary endpoint was presence of treatment-related adverse events (TRAEs).</p><p><strong>Results: </strong>The median follow-up was 7.8 months (95%CI: 5.0-11.8 months). The objective response rate was 60.0% (18/30), while the disease control rate was 93.3%. The median duration of response in confirmed responders was 6.6 months (95%CI: 1.3-12.9 months). The median progression-free survival was 11.8 months (95%CI: 8.3-15.4 months). More than half of the patients survived until the end of the study. Grade > 3 TRAEs occurred in 40% of the patients with no grade 5 TRAEs reported. The most common grade 3/4 TRAE was palmar-plantar erythrodysesthesia, a dermatologic condition characterized by painful redness and swelling of the palms and soles, with an incidence of 56.7%. No ICI-related adverse effects were observed.</p><p><strong>Conclusion: </strong>TACE combined with donafenib and ICI is a promising and safe therapeutic regimen for unresectable HCC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105170"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of hepatocellular carcinoma according to body mass index and waist circumference in nonalcoholic fatty liver disease.","authors":"Han Na Jung, Ji Hye Heo, Eun Roh, Bum Jun Kim, Minwoo Lee, Jwa-Kyung Kim, Joo-Hee Kim, Boram Han, Kyung-Do Han, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm","doi":"10.4251/wjgo.v17.i6.107364","DOIUrl":"10.4251/wjgo.v17.i6.107364","url":null,"abstract":"<p><strong>Background: </strong>The association between adiposity parameters and incident hepatocellular carcinoma (HCC) in individuals with nonalcoholic fatty liver disease (NAFLD) is yet to be evaluated.</p><p><strong>Aim: </strong>To investigate the risk of HCC according to body mass index (BMI) and waist circumference (WC) in people with NAFLD.</p><p><strong>Methods: </strong>This population-based cohort study included Korean National Health Insurance Service examination participants with NAFLD (<i>n</i> = 1110773). NAFLD was defined as a fatty liver index of ≥ 30. The risk of HCC was determined by Cox proportional hazards regression according to BMI and WC after adjusting for age, sex, health behaviors, income, comorbidities, and WC or BMI.</p><p><strong>Results: </strong>HCC was diagnosed in 4773 (0.43%) participants during a median follow-up of 10.3 years. A U-shaped association between BMI or WC and HCC was observed, with the highest risk observed in the lowest BMI and WC groups. Compared to normal BMI, the adjusted hazard ratio (aHR) of the underweight BMI group was 2.02 [95% confidence interval (CI): 1.25-3.28]. The lowest risk was found in groups with overweight BMI (aHR = 0.67, 95%CI: 0.60-0.73; reference: normal BMI) and WC: 85-89.9/80-84.9 cm for men/women (aHR = 0.55, 95%CI: 0.49-0.63; reference: < 80/< 75 cm). Subgroup analyses of age, sex, health behaviors, and fatty liver index showed consistent results.</p><p><strong>Conclusion: </strong>The development of HCC shows a U-shaped relationship with BMI and WC in people with NAFLD, with the highest risk in underweight individuals.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"107364"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence to predict hepatocellular carcinoma risk in cirrhosis.","authors":"Imen Akkari, Hanen Akkari, Raida Harbi","doi":"10.4251/wjgo.v17.i6.107414","DOIUrl":"10.4251/wjgo.v17.i6.107414","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. The primary risk factor for HCC is cirrhosis. Identifying individuals who are at high risk of developing HCC will have numerous benefits for patient outcomes, patient quality of life, and the global healthcare system. Artificial intelligence (AI) has the capability to develop systems that emulate human intelligence. Recent studies have highlighted the potential of AI in the management of HCC, and the application of AI appears promising for identifying high-risk groups among patients with cirrhosis who require closer monitoring. Ultimately, the aim of AI in the field of HCC clinical care is to enable earlier diagnosis and consequently improve prognosis.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"107414"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive lymphadenectomy for gastric cancer: Could the robotic approach provide any benefits than laparoscopy?","authors":"Daniele Marrelli, Ludovico Carbone, Gianmario Edoardo Poto, Daniele Fusario, Mattheus Gjoka, Eleonora Andreucci, Stefania Angela Piccioni, Natale Calomino, Marta Sandini, Franco Roviello","doi":"10.4251/wjgo.v17.i6.104015","DOIUrl":"10.4251/wjgo.v17.i6.104015","url":null,"abstract":"<p><p>Gastrectomy is the cornerstone of treatment for gastric cancer. Since the introduction of minimally invasive techniques, the main challenge for surgeons has been to achieve the same surgical radicality, adequate lymphadenectomy, and negative resection margins as with the open approach. Previous Eastern trials showed non-inferiority of laparoscopic gastrectomy, whereas Western trials reported a higher number of complications. This may depend on the different eligibility criteria to select patients and surgeons. Currently, the increased availability of robotic systems has led to renewed enthusiasm. We present a critical review of published randomized control trials (up to October 2024) to investigate the real benefits of robotic compared to open and laparoscopic approaches. Robotic gastrectomy has shown similar oncological outcomes in survival and lymph node retrieval, particularly in suprapancreatic stations, with the advantage of a more acceptable rate of pancreatic fistula and feasible anastomotic reconstruction. Some clinical situations, such as postchemotherapy interstitial fibrosis and distortion of anatomical planes, may increase the technical difficulty. Only four published trials assessed the implications of a pre-operative therapy, with no robotic surgery cases. Robotic systems may reduce intraoperative blood loss, the risk of conversion and allow more extensive lymphadenectomies in cancers with a high risk of extraperigastric metastases, or with clinically proven para-aortic node metastases, although clinical trials evaluating robotic gastrectomy after neoadjuvant therapy have not yet been published.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"104015"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}